摘要
目的评价依达拉奉治疗急性脑梗死的临床疗效及其安全性。方法80例急性脑梗死病人随机分为治疗组和对照组。两组基础治疗相同,治疗组接受依达拉奉注射液30mg加入生理盐水250mL静脉输注,每日2次,14d为1个疗程。对照组接受胞二磷胆碱治疗500mg加入生理盐水250mL中静脉输注,每日1次,14d为1个疗程。第14天时评定两组总疗效,并采用中国卒中量表(CSS)、Barthel指数(BI)评价神经功能恢复状况。结果14d后治疗组总有效率达82.5%,对照组总有效率达67.5%,两组疗效比较有统计学意义(P<0.05);治疗组CSS评分降低优于对照组,BI明显高于对照组(P<0.05)。两组均未发现明显副反应。结论依达拉奉可用于治疗急性脑梗死,能有效改善神经功能缺损及日常生活能力,是一种安全有效的药物。
Objective To evaluate the efficacy and safety of edaravone for acute cerebral infarctions. Methods Eighty patients （pts） were divided into treatment group and control group randomly. Pts in treatment group received edaravone, and pts in control group received citicoline. China Stroke Scale （CSS） and Barthel Index （BI） were used to evaluate the recovery of neurological functions. Results At 14th day the efficiency rate in treatment group was 82.5%, and that in control group was 67.5% （P〈0. 05）. There were no distinct adverse reactions in two groups. Conclusion Edaravone was effective and safe for acute cerebral infarctions.
出处
《中西医结合心脑血管病杂志》
2007年第3期205-207,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金
广东省梅州市医药卫生科研基金课题项目(No.2004-B-52)
关键词
依达拉奉
脑梗死
自由基清除剂
edaravone
cerebral infarction
free radical scavenger
